Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers

Share this content:
Approximately one-third of patients with NSCLC with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy.
Approximately one-third of patients with NSCLC with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy.

Adding next-generation sequencing (NGS), using plasma samples, to the routine management of metastatic non-small cell lung cancer (NSCLC) has the potential to improve the delivery of targeted therapy by increasing the detection of targetable mutations, according to a recent study.1

The study included 323 patients with metastatic NSCLC who were undergoing plasma testing as part of routine management of their disease. Plasma NGS was done using a 73-gene commercial platform. Of the 323 patients, 229 had concurrent plasma and tissue NGS or were unable to complete tissue testing.

Use of tissue testing only found targetable mutations for 20.5% of patients. In contrast, adding plasma NGS increased the rate of targetable mutation discovery to 35.8% of patients. The researchers noted that 33% of patients with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy. 

Overall, 67 patients received a targeted therapy based on the results from NGS testing. Some identified targets included EGFR, ALK, BRAF, BRCA1, and MET.  Of 42 patients with evaluable treatment results, 85.7% achieved either complete response, partial response, or stable disease.

In an editorial that accompanied the study, Bishal Gyawali, MD, PhD, of Brigham and Women's Hospital, Boston, Massachusetts; and Howard West, MD, of the Swedish Cancer Institute, Seattle, Washington, concluded that these results do not yet show that plasma NGS can replace tissue testing, as about one-third of patients with a targetable mutation who had tissue and plasma NGS testing had a mutation found only in the tissue. However, they added that “the study compellingly demonstrates that plasma NGS can obviate the need for tissue NGS in patients in whom plasma testing demonstrates a mutation, given the response and disease control rate among patients who had therapeutically targetable mutations identified from plasma.”

References

  1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer [published online October 11, 2018]. JAMA Oncol. doi: 10.1001/jamaoncol.2018.4305
  2. Gyawali B, West H. Plasma vs tissue next-generation sequencing in non-small cell lung cancer — either, both, or neither? [published online October 11, 2018]. JAMA Oncol. doi: 10.1001/jamaoncol.2018.4304

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs